Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03150056
Registration number
NCT03150056
Ethics application status
Date submitted
9/05/2017
Date registered
11/05/2017
Date last updated
10/08/2022
Titles & IDs
Public title
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
Query!
Scientific title
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Query!
Secondary ID [1]
0
0
2016-003416-13
Query!
Secondary ID [2]
0
0
204697
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Solid Tumours
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GSK525762
Treatment: Drugs - Abiraterone
Treatment: Drugs - Enzalutamide
Treatment: Drugs - Prednisone
Experimental: GSK525762 + Abiraterone (+ Prednisone) (Arm A) -
Experimental: GSK525762 + Enzalutamide (Arm B) -
Treatment: Drugs: GSK525762
GSK525762 will be administered.
Treatment: Drugs: Abiraterone
Abiraterone will be administered.
Treatment: Drugs: Enzalutamide
Enzalutamide will be administered.
Treatment: Drugs: Prednisone
Prednisone will be administered as a concomitant medication in combination with abiraterone
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement, or is associated with liver injury and impaired liver function.
Query!
Timepoint [1]
0
0
Up to 21.3 months
Query!
Primary outcome [2]
0
0
Number of Participants With AEs Leading to Any Dose Reduction or Delays
Query!
Assessment method [2]
0
0
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to any dose reduction or delays have been presented.
Query!
Timepoint [2]
0
0
Up to 21.3 months
Query!
Primary outcome [3]
0
0
Number of Participants Who Withdrew Due to Toxicity and Changes in Safety Assessment
Query!
Assessment method [3]
0
0
Number of participants who withdrew due to toxicity and changes in safety assessment including laboratory parameters and vital signs have been presented.
Query!
Timepoint [3]
0
0
Up to 21.3 months
Query!
Primary outcome [4]
0
0
Percentage of Participants With Greater Than or Equals to (>=)50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)
Query!
Assessment method [4]
0
0
PSA50 response rate is defined as percentage of participants with a decrease of >=50% in the PSA concentration from the Baseline PSA value determined at least 12 weeks after start of treatment and confirmed >=4 weeks later by an additional PSA evaluation.
Query!
Timepoint [4]
0
0
Up to 21.3 months
Query!
Secondary outcome [1]
0
0
Maximum Observed Plasma Concentration (Cmax) of GSK525762 and Its Active Metabolites GSK3529246
Query!
Assessment method [1]
0
0
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis. PK Population consisted of all participants from the All Treated Safety Population for whom a PK sample was obtained and analyzed.
Query!
Timepoint [1]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [2]
0
0
Time to Cmax (Tmax) of GSK525762 and Its Active Metabolites GSK3529246
Query!
Assessment method [2]
0
0
Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [2]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [3]
0
0
Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUC[0-tau]) of GSK525762 and Its Active Metabolites GSK3529246
Query!
Assessment method [3]
0
0
Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [3]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [4]
0
0
Trough Concentration (Ctrough) of GSK525762 and Its Active Metabolites GSK3529246
Query!
Assessment method [4]
0
0
Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [4]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [5]
0
0
Cmax of Abiraterone
Query!
Assessment method [5]
0
0
Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [5]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [6]
0
0
Tmax of Abiraterone
Query!
Assessment method [6]
0
0
Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [6]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [7]
0
0
AUC(0-tau) of Abiraterone
Query!
Assessment method [7]
0
0
Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [7]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [8]
0
0
Ctrough of Abiraterone
Query!
Assessment method [8]
0
0
Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [8]
0
0
Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Day 1 of Weeks 1 and 3
Query!
Secondary outcome [9]
0
0
Cmax of Enzalutamide
Query!
Assessment method [9]
0
0
Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [9]
0
0
Pre-dose on Day 1 of Weeks 1, 3, 5, 9, 17 and 25
Query!
Secondary outcome [10]
0
0
Tmax of Enzalutamide
Query!
Assessment method [10]
0
0
Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [10]
0
0
Pre-dose on Day 1 of Weeks 1, 3, 5, 9, 17 and 25
Query!
Secondary outcome [11]
0
0
AUC(0-tau) of Enzalutamide
Query!
Assessment method [11]
0
0
Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [11]
0
0
Pre-dose on Day 1 of Weeks 1, 3, 5, 9, 17 and 25
Query!
Secondary outcome [12]
0
0
Ctrough of Enzalutamide
Query!
Assessment method [12]
0
0
Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.
Query!
Timepoint [12]
0
0
Pre-dose on Day 1 of Weeks 1, 3, 5, 9, 17 and 25
Query!
Secondary outcome [13]
0
0
Disease Control Rate at Week 24
Query!
Assessment method [13]
0
0
Disease control rate (DCR) is defined as the percentage of participants with >=1 post-Baseline disease assessment who showed either a confirmed complete response (CR), partial response (PR) or stable disease (SD) observed at >=24 weeks per prostate cancer working group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; where CR: disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeter in the short axis; PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive diseases. Confidence interval (CI) was computed using exact two sided 95% CI.
Query!
Timepoint [13]
0
0
Week 24
Query!
Secondary outcome [14]
0
0
Composite Response Rate
Query!
Assessment method [14]
0
0
Composite response rate was defined as the percentage of participants with one of the following: a) Response based on PCWG3-modified RECIST version 1.1, b) PSA decrease of >=50% from Baseline at Week 12 and thereafter, or c) Circulating Tumor-cell Count Conversion from unfavorable (>=5/7.5 milliliter [mL]) at Baseline to favorable (<5/7.5 mL) confirmed by a second assessment at least 4 weeks later. If a participant met at least one of the above requirements, then that participant was considered a composite responder. CI was computed using exact two sided 95% CI.
Query!
Timepoint [14]
0
0
Up to 21.3 months
Query!
Secondary outcome [15]
0
0
Objective Response Rate
Query!
Assessment method [15]
0
0
Objective response rate (ORR) is defined as the percentage of participants with a confirmed CR or PR at any time as per PCWG3-modified RECIST version 1.1; where CR: Disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeter (mm) in the short axis and PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.
Query!
Timepoint [15]
0
0
Up to 21.3 months
Query!
Secondary outcome [16]
0
0
Circulating Tumor Cells (CTC) Response Rate
Query!
Assessment method [16]
0
0
CTC response rate is defined as the percentage of participants with a CTC conversion to <5/7.5 mL blood at nadir (confirmed by a second consecutive value obtained four or more weeks later) for participants with unfavourable CTC (>=5/7.5 mL) at Baseline. CI was computed using exact two sided 95% CI.
Query!
Timepoint [16]
0
0
Up to 21.3 months
Query!
Secondary outcome [17]
0
0
Prostate-specific Antigen (PSA) Response Rate at Week 4
Query!
Assessment method [17]
0
0
PSA Response Rate is defined as percentage of participants achieving >=30% decrease from Baseline PSA after 4 weeks of study treatment. The CI was calculated using exact two sided 95% CI for the percentage of participants with Baseline PSA values who show >=30% reduction in PSA at >=4 weeks post-Baseline.
Query!
Timepoint [17]
0
0
Week 4
Query!
Secondary outcome [18]
0
0
Time to Disease Progression
Query!
Assessment method [18]
0
0
Time to disease progression is defined as the time from date of first dose of study treatment to date of disease progression defined as one or more of the following criteria: 1. Radiographic progression by PCWG3-modified RECIST version 1.1 for participants with measurable disease, 2. Bone progression on bone scan according to the PCGW3 criteria, 3. PSA progression according to the PCWG3 criteria accompanied by any one of the following: investigator-defined clinical progression or either of the above RECIST version 1.1 radiographic progression or bone progression.
Query!
Timepoint [18]
0
0
Up to 21.3 months
Query!
Secondary outcome [19]
0
0
Radiographic Progression-free Survival (rPFS)
Query!
Assessment method [19]
0
0
rPFS is defined as the time from study treatment start until the first date of either disease progression or death due to any cause. The date of disease progression is defined as the earliest date of disease progression as assessed by the investigator using PCWG3-modified RECIST, version 1.1 or progression on bone scan. Progressive disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started.
Query!
Timepoint [19]
0
0
Up to 21.3 montths
Query!
Secondary outcome [20]
0
0
Number of Participants With Worst-Case Post Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status
Query!
Assessment method [20]
0
0
Performance status assessments were based on 6-point ECOG scale (from 0 to 5), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; and 5=dead. Data for worst case post-Baseline is presented.
Query!
Timepoint [20]
0
0
Up to 21.3 months
Query!
Secondary outcome [21]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS)
Query!
Assessment method [21]
0
0
EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included 5 functional scales (physical functioning, role functioning, cognitive functioning, emotional functioning and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options for GHS/QoL range from 1 to 4, where 1=not at all and 4=very much. Scores were averaged and transformed to a 0 to 100 scale, with higher scores representing a high QoL. Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose. Change from Baseline was calculated as post-Baseline visit value minus Baseline value.
Query!
Timepoint [21]
0
0
Baseline (Week 1 Day 1, pre-dose) and on Day 1 of Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61
Query!
Secondary outcome [22]
0
0
Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF): Pain Intensity- Pain at Worst in Last 24 Hours
Query!
Assessment method [22]
0
0
BPI-SF is 9-item self-administered questionnaire. Pain intensity score was calculated from the four items (items 3, 4, 5 and 6) for worst pain, least pain, average pain and current pain. Worst pain in last 24 hours was rated from 0 (no pain) to 10 (pain as bad as you can imagine). Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose (latest up to Week 1 Day 1). Change from Baseline was calculated as post-Baseline visit value minus Baseline value.
Query!
Timepoint [22]
0
0
Baseline (Pre-dose on Week 1 Day 1) and on Day 1 of Weeks 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61, 73, 85, 97
Query!
Eligibility
Key inclusion criteria
- Written informed consent provided.
- Males >=18 years of age (at the time written consent is obtained for screening).
- Histologically confirmed adenocarcinoma of the prostate: screening and on-treatment
biopsy is mandatory. If adequate number of paired biopsy samples are collected (>=20
paired samples for each dose level in each Arm, unless an Arm is closed early), then
further biopsy sampling will be considered based on available data; screening biopsy
can be waived if participant had a recent biopsy after failure of the most recent
therapy (within 30 days) and the biopsy sample is secured to be sent as screening
biopsy for this study.
- Surgically or medically castrated, with testosterone levels of less than or equal to
(<=)50 nanograms per deciliter (ng/dL) (<2.0 nanometer [nM]). If the participant is
being treated with luteinizing hormone-releasing hormone (LHRH) agonists/antagonists
(participant who have not undergone orchiectomy) this therapy must have been initiated
at least 4 weeks prior to Week 1 Day 1 and must be continued throughout the study.
- Participants must have failed prior therapy with abiraterone, enzalutamide, or both:
1. Has completed at least 12 weeks of prior continuous therapy with abiraterone or
enzalutamide in any prior line.
2. Lead-in dosing period for enzalutamide only will be required under the following
circumstance:
(i) If the participant has enzalutamide discontinuation for >7 days prior to dosing
start with GSK525762 plus enzalutamide on trial, then a enzalutamide only lead-in
dosing of 28 days is required.
(ii) If the participant has enzalutamide discontinuation for <=7 days prior to dosing start
with GSK525762 plus enzalutamide on trial, then an enzalutamide only lead-in dosing of 14
days is required.
(iii) If the participant is on continuous dosing with enzalutamide prior to dosing start
with GSK525762 plus enzalutamide on trial, then participant can start on combined dosing at
end of screening period.
(c) Lead-in dosing period for abiraterone only will be required: if the participant has
abiraterone discontinuation for more than 3 days prior to dosing start with GSK525762 plus
abiraterone on trial, then abiraterone only lead-in dosing of 7 days is required.
- One to two line(s) of prior taxane-based chemotherapy allowed. If docetaxel
chemotherapy is used more than once, this will be considered as one regimen.
Participants who have not received prior chemotherapy in any setting will qualify for
study if they are ineligible for or refuse chemotherapy.
- Documented prostate cancer progression as assessed by the investigator with one of the
following:
1. PSA progression defined by a minimum of 3 rising PSA levels with an interval of
>=1 week between each determination. The PSA value at screening must be >=5
microgram (µg)/Liter (L) (5 ng/mL) if PSA is the only indication of progression;
participants on systemic glucocorticoids for control of symptoms must have
documented PSA progression by PCWG3 while on systemic glucocorticoids prior to
commencing Week 1 Day 1 treatment.
2. Radiographic progression of soft tissue disease by PCWG3-modified RECIST 1.1
criteria or bone metastasis with 2 or more documented new bone lesions on a bone
scan with or without PSA progression.
- ECOG performance status of 0 or 1.
- Life expectancy >12 weeks.
- Able to swallow and retain orally administered medication.
- Must have adequate organ function.
- Male participants are eligible to participate if they agree to use contraceptive
methods.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Surgery or local prostatic intervention (excluding a prostatic biopsy) less than 28
days of Week 1 Day 1.
- Participants with neuroendocrine and/or small cell CRPC.
- Recent prior therapy, defined as:
1. Any investigational or approved non-biologic anti-cancer drug within 14 days
prior to the first dose of GSK525762 and abiraterone/enzalutamide.
2. Any nitrosoureas or mitomycin C within 42 days prior to the first dose of
GSK525762 and abiraterone/enzalutamide.
3. Any anti-cancer biologic agents within five half-lives prior to the first dose of
GSK525762 and abiraterone/enzalutamide.
4. If the participant received radiotherapy <90 days prior to study treatment, the
irradiated lesion cannot be the only lesion used for evaluating response.
5. Any major surgery within 28 days prior to the first dose of GSK525762 and
abiraterone/enzalutamide.
- Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated
respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding
episodes). Any serious and/or unstable pre-existing medical (aside from malignancy),
psychiatric disorder, or other conditions that could interfere with participant's
safety, obtaining informed consent or compliance to the study procedures, in the
opinion of the Investigator; systolic blood pressure higher than 150 millimeter of
mercury (mmHg) or diastolic blood pressure higher than 90 mmHg found on 2 separate
occasions separated by 1 week, despite adequate therapy, will be defined as
uncontrolled hypertension; uncontrolled diabetes mellitus (despite therapeutic,
compliance intervention) as defined by a hemoglobin A1c (HbA1c) level more than 8%
and/or occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to
the first dose of study drug.
- Cardiac abnormalities as evidenced by any of the following:
1. Baseline QT interval corrected for heart rate by Fridericia's formula (QTcF)
interval >=480 milliseconds (msec).
2. Clinically significant conduction abnormalities or arrhythmias, such as
participants with second degree (Type II) or third degree atrio-ventricular
block.
3. History or evidence of current >=Class II congestive heart failure as defined by
New York Heart Association (NYHA).
4. History of acute coronary syndromes (including unstable angina and myocardial
infarction), coronary angioplasty, or stenting within the past 3 months.
Participants with a history of stent placement requiring ongoing anti-coagulant
therapy (e.g., clopidogrel, prasugrel) will not be permitted to enroll.
5. Known cardiac metastasis.
- Participants with history of known bleeding disorder(s) or history of clinically
significant hemorrhage (e.g., gastrointestinal, neurologic), within the past 6 months.
- Therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin [LMWH],
or novel oral anticoagulants) must be discontinued and coagulation parameters must be
normalized prior to the first dose of GSK525762 and abiraterone/enzalutimide.
Prophylactic anticoagulation, with low doses (per standard practice) of agents such as
LMWH, direct thrombin inhibitors, or factor Xa inhibitors is permitted.
- Concurrent use of high dose aspirin (doses up to 81 milligrams (mg) oral dose daily
allowed, or 100 mg, as per country standards) and non-steroidal anti-inflammatory
drugs (NSAIDS), except for where NSAIDs provide documented benefit over other
analgesics, and then to be used with caution including concomitant use of proton pump
inhibitors).
- Any acute toxicities due to prior chemotherapy and / or radiotherapy that have not
resolved to a National Cancer Institute-Common Terminology Criteria for Adverse Events
(NCI-CTCAE) version 4.0 grade <=1 with the exception of chemotherapy induced alopecia
and grade 2 peripheral neuropathy.
- The participant has an active second malignancy other than curatively resected basal
cell or squamous cell carcinoma of the skin, in situ carcinoma of the bladder, or
other cancers for which they are treated with curative intent with no active disease
in the 3 years prior to enrollment.
- Participants with known symptomatic brain metastasis are not suitable for enrolment.
Participants with asymptomatic, stable, treated brain metastases are eligible for
study entry.
- History of seizure within 6 months of study treatment initiation or any condition that
may predispose participant to seizure (e.g., prior cortical stroke or significant
brain trauma) or who are currently being treated with cytochrome P450 enzyme inducing
anti-epileptic drugs for seizures (use of anti-epileptic drugs to control pain is
allowed in participants not suffering from seizures unless drug is excluded due to
Cytochrome (CY)P3A4 induction - phenytoin, carbamazepine, phenobarbital).
- History of loss of consciousness or transient ischemic attack within 12 months prior
to enrollment.
- Participants with symptomatic or impending cord compression unless appropriately
treated beforehand and clinically stable and asymptomatic.
- Current use of a prohibited medication or planned use of any forbidden medications
during treatment with GSK525762 and abiraterone/enzalutamide. This includes
medications that are potent inducers or inhibitors of CYP3A4 enzymes or strong
inhibitors of CYP2C8.
- Participants with gastrointestinal disorders likely to interfere with absorption of
the study medication.
- Participants with known bleeding diathesis.
- Current active liver or biliary disease (with the exception of Gilbert's syndrome or
asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease
per investigator assessment).
- Initiating bisphosphonate or denosumab therapy or adjusting dose/regimen within 3
months prior to Week 1 Day 1. Participants on a stable bisphosphonate or denosumab
therapy are eligible and may continue.
- Any serious known immediate or delayed hypersensitivity reaction to GSK525762 or
idiosyncrasy to drugs chemically related to the investigational drugs. Additionally,
any known hypersensitivity to either enzalutamide, abiraterone or any excipients would
be excluded.
- Known history of human immunodeficiency virus (HIV).
- Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test
result at screening.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/07/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/06/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
73
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Sydney
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Clayton
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2050 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3000 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Maryland
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Michigan
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Wisconsin
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Barcelona
Query!
Country [10]
0
0
Spain
Query!
State/province [10]
0
0
Madrid
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Malaga
Query!
Country [12]
0
0
Spain
Query!
State/province [12]
0
0
Sabadell (Barcelona)
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Santander
Query!
Country [14]
0
0
United Kingdom
Query!
State/province [14]
0
0
London
Query!
Country [15]
0
0
United Kingdom
Query!
State/province [15]
0
0
Glasgow
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study aims to evaluate the combination of GSK525762 with other agents that have been
shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed
to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on
safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with
either abiraterone (Arm A) or enzalutamide (Arm B).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03150056
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03150056
Download to PDF